Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks

Theravance Biopharma, Inc.

2023-Q2 EPS reported -$0.63 revenue$24,166,000

YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.
YUPELRI retail TRx and new-to-product TRx hit all-time highs, up 26% and 53% YoY (Symphony Health).
PIFR-2 enrollment nearing completion; top-line data late Q4 2023, disclosure expected Jan 2024.
$80.5M share repurchases in Q2 2023 ($263.8M cumulative); $61.2M remaining in $325M program to complete by year-end.
TRELEGY ELLIPTA Q2 global net sales $760M (+29% YoY); $50M milestone from Royalty Pharma if 2023 sales ≥ $2.9B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.